Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
Hosted on MSN3d
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...
A still from the 2025 Super Bowl commercial “Sick of the System,” from telehealth company Hims & Hers. © 2025 Fortune Media IP Limited. All Rights Reserved. Use ...
GLP-1 agonist semaglutide is the active ingredient ... health risks – particularly with complex injectable products like Hims & Hers is advertising," he added. "The FDA says compounded drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback